Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells.

Viganò S, Bellutti Enders F, Miconnet I, Cellerai C, Savoye AL, Rozot V, Perreau M, Faouzi M, Ohmiti K, Cavassini M, Bart PA, Pantaleo G, Harari A.

PLoS Pathog. 2013;9(7):e1003423. doi: 10.1371/journal.ppat.1003423. Epub 2013 Jul 4.

2.

Probing the T-cell receptor repertoire with deep sequencing.

Miconnet I.

Curr Opin HIV AIDS. 2012 Jan;7(1):64-70. doi: 10.1097/COH.0b013e32834ddcae. Review.

PMID:
22156841
3.

Large TCR diversity of virus-specific CD8 T cells provides the mechanistic basis for massive TCR renewal after antigen exposure.

Miconnet I, Marrau A, Farina A, Taffé P, Vigano S, Harari A, Pantaleo G.

J Immunol. 2011 Jun 15;186(12):7039-49. doi: 10.4049/jimmunol.1003309. Epub 2011 May 9.

4.

Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection.

Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, Ding XC, Chanson AL, Reymond MK, Miconnet I, Schrenzel J, François P, Calandra T.

Blood. 2011 Jan 27;117(4):1205-17. doi: 10.1182/blood-2010-05-284711. Epub 2010 Oct 18.

5.

A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response.

Miconnet I, Pantaleo G.

Vaccine. 2008 Jul 29;26(32):4006-14. doi: 10.1016/j.vaccine.2008.05.028. Epub 2008 Jun 2.

PMID:
18562050
6.

Induction of multiple CD8+ T cell responses against the inducible Hsp70 employing an Hsp70 oligoepitope peptide.

Faure O, Graff-Dubois S, Alves PM, Cornet S, Duffour MT, Scardino A, Gross DA, Miconnet I, Salcedo M, Chouaib S, Lemonnier FA, Abastado JP, Kosmatopoulos K.

Oncol Rep. 2007 Mar;17(3):679-85.

PMID:
17273751
7.

A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies.

Mavroudis D, Bolonakis I, Cornet S, Myllaki G, Kanellou P, Kotsakis A, Galanis A, Nikoloudi I, Spyropoulou M, Menez J, Miconnet I, Niniraki M, Cordopatis P, Kosmatopoulos K, Georgoulias V.

Oncology. 2006;70(4):306-14. Epub 2006 Oct 12.

PMID:
17047402
8.

STEAP, a prostate tumor antigen, is a target of human CD8+ T cells.

Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA, Kosmatopoulos K.

Cancer Immunol Immunother. 2006 Dec;55(12):1515-23. Epub 2006 Apr 19.

PMID:
16622681
9.

Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity.

Cornet S, Miconnet I, Menez J, Lemonnier F, Kosmatopoulos K.

Vaccine. 2006 Mar 15;24(12):2102-9. Epub 2005 Nov 28.

PMID:
16455166
10.

CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.

Cornet S, Menez-Jamet J, Lemonnier F, Kosmatopoulos K, Miconnet I.

Vaccine. 2006 Mar 10;24(11):1880-8. Epub 2005 Oct 28.

PMID:
16300869
11.

Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression.

Roger T, Miconnet I, Schiesser AL, Kai H, Miyake K, Calandra T.

Biochem J. 2005 Apr 15;387(Pt 2):355-65.

12.

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, Lemonnier FA, Davoust J, Miconnet I, Vonderheide RH, Kosmatopoulos K.

J Clin Invest. 2004 Feb;113(3):425-33.

13.

Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes.

Faure O, Graff-Dubois S, Bretaudeau L, Derré L, Gross DA, Alves PM, Cornet S, Duffour MT, Chouaib S, Miconnet I, Grégoire M, Jotereau F, Lemonnier FA, Abastado JP, Kosmatopoulos K.

Int J Cancer. 2004 Mar 1;108(6):863-70.

14.

EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes.

Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K.

Cancer Res. 2003 Dec 1;63(23):8476-80.

15.

In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses.

Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Lévy F, MacDonald HR.

J Clin Invest. 2003 Jun;111(11):1673-81.

16.

Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen.

Wirth S, Bille F, Koenig S, Wehrli N, Miconnet I, Lévy F, Diggelmann H, Romero P, Acha-Orbea H.

Int J Cancer. 2002 May 10;99(2):201-6.

17.

CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.

Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC, Romero P.

J Immunol. 2002 Feb 1;168(3):1212-8.

18.

OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway.

Jeannin P, Renno T, Goetsch L, Miconnet I, Aubry JP, Delneste Y, Herbault N, Baussant T, Magistrelli G, Soulas C, Romero P, Cerottini JC, Bonnefoy JY.

Nat Immunol. 2000 Dec;1(6):502-9.

PMID:
11101872
19.

Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction.

Miconnet I, Coste I, Beermann F, Haeuw JF, Cerottini JC, Bonnefoy JY, Romero P, Renno T.

J Immunol. 2001 Apr 1;166(7):4612-9.

20.

Amino acid identity and/or position determines the proteasomal cleavage of the HLA-A*0201-restricted peptide tumor antigen MAGE-3271-279.

Miconnet I, Servis C, Cerottini JC, Romero P, Lévy F.

J Biol Chem. 2000 Sep 1;275(35):26892-7.

21.

Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.

Valmori D, Lévy F, Miconnet I, Zajac P, Spagnoli GC, Rimoldi D, Liénard D, Cerundolo V, Cerottini JC, Romero P.

J Immunol. 2000 Jan 15;164(2):1125-31.

22.

Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice.

Men Y, Miconnet I, Valmori D, Rimoldi D, Cerottini JC, Romero P.

J Immunol. 1999 Mar 15;162(6):3566-73.

23.
24.

Peripheral tolerance to host minor histocompatibility antigens in radiation bone marrow chimeras abrogates lethal GVHD while preserving GVL effect.

de la Selle V, Miconnet I, Gilbert D, Bruley-Rosset M.

Bone Marrow Transplant. 1995 Jul;16(1):111-8.

PMID:
7581109
25.

Critical role of endogenous Mtv in acute lethal graft-versus-host disease.

Miconnet I, Roger T, Seman M, Bruley-Rosset M.

Eur J Immunol. 1995 Feb;25(2):364-8.

PMID:
7875197
26.

Coding sequence polymorphism of Tcrg-V1, -V2, and -V4 genes in mice bearing Tcr-gA and -gC haplotypes.

Roger T, Miconnet I, Bruley-Rosset M, Seman M.

Immunogenetics. 1994;39(1):68-70. No abstract available.

PMID:
8225440
27.

Tissue distribution and polymorphism of minor histocompatibility antigens involved in GVHR.

Miconnet I, de la Selle V, Tucek C, Huchet R, Bonardelle D, Bruley-Rosset M.

Immunogenetics. 1994;39(3):178-86.

PMID:
7903960
28.

Rearrangement by chromosomal inversion in the T cell receptor gamma locus in a murine alpha beta T cell clone.

Roger T, Miconnet I, Bruley-Rosset M, Seman M.

Mol Immunol. 1993 Dec;30(17):1617-20.

PMID:
8247032
29.

Comparison of the repertoire of T-cell lines and clones specific for minor histocompatibility antigens derived from immunized mice and from mice developing a graft-versus-host reaction.

Bruley-Rosset M, Miconnet I, Roger T, Seman M, Halle-Pannenko O.

Transplant Proc. 1993 Feb;25(1 Pt 1):94-5. No abstract available.

PMID:
8438503
30.
31.

[T clones, a means of exploring minor antigens involved in graft versus host reaction].

Miconnet I.

Presse Med. 1992 Dec 2;21(41):1947-50. French.

PMID:
1294947
33.

Mlsa generated suppressor cells. I. Suppression is mediated by double-negative (CD3+CD5+CD4-CD8-) alpha/beta T cell receptor-bearing cells.

Bruley-Rosset M, Miconnet I, Canon C, Halle-Pannenko O.

J Immunol. 1990 Dec 15;145(12):4046-52.

PMID:
1701781
34.

Graft-versus-host mortality induced by noncytolytic CD4+ T cell clones specific for non-H-2 antigens.

Miconnet I, Huchet R, Bonardelle D, Motta R, Canon C, Garay-Rojas E, Kress M, Reynes M, Halle-Pannenko O, Bruley-Rosset M.

J Immunol. 1990 Oct 1;145(7):2123-31.

PMID:
1697877

Supplemental Content

Loading ...
Support Center